Title: Is Glucose-6-Phosphate Dehydrogenase Deficiency a Risk Factor for Proliferative Diabetic Retinopathy in Male Patients with Type 1 Diabetes Mellitus in Basrah?
Authors: Hussein Ali Nwayyir- MD, Abbas Ali Mansour - MD, FRCP, FACE
DOI: https://dx.doi.org/10.18535/jmscr/v5i1.07
Abstract
Background: Diabetes Mellitus is a chronic and common disease with diabetic retinopathy a frequent long-term complication.Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most prevalent human enzyme defect. Both of these conditions are very common in our locality with many burdens on the patients' quality of life and health care services.
Aim: To search for any significant association between G6PD deficiency and the development of proliferative diabetic retinopathy (PDR) among male patient with type 1 diabetes mellitus (T1DM).
Method: A case-control study was conducted onNinety-four adult male patients with T1DM in Al Faiha Diabetes, Endocrine and Metabolism Center over a two-year period from October 2012 to October 2014. All patients are submitted to both funduscopicexaminations of their eyes and G6PD assay.
Results: PDR is found among 7.6% of those who were G6PD sufficient in comparison to 42.9% of G6PD deficient (p-value<0.001).
Conclusion: There is a significant association between G6PD deficiency status and the development of PDR in male patients with T1DM.
Keywords: type 1 diabetes mellitus, Glucose-6-phosphate dehydrogenase (G6PD) deficiency, and proliferative diabetic retinopathy.
References
2. Liese AD, D’Agostino RB Jr., Hamman RF, Kilgo PD, Lawrence JM, Liu LL et al. The burden of diabetes mellitus among US youth: prevalence estimates from the SEARCH for Diabetes in Youth Study. Peds. 2006;118:1510–8.
3. Vandewalle CL, Coeckelberghs MI, De Leeuw IH, Du Caju MV, Schuit FC, Pipeleers DGet al. Epidemiology, clinical aspects, and biology of IDDM patients under age 40 years. Comparison of data from Antwerp with complete ascertain-ment with data from Belgium with 40% ascertainment. The Belgian Diabetes Registry. Diabetes care. 1997;20:1556–61.
4. Thunander M, Petersson C, JonzonK, Fornander J, Ossiansson B, Torn C et al. Incidence of type 1 and type 2 diabetes in adults and children in Kronoberg, Sweden. Diabetes Res Clin Pract. 2008;82:247–55.
5. Dabelea D, Bell RA, D’Agostino RB Jr, Imperatore G, Johansen JM, Linder B et al. Incidence of diabetes in youth in the United States. JAMA.2007;297:2716–24.
6. DIAMOND Project Group.Incidence and trends of childhood Type 1 diabetes worldwide 1990–1999. Diabet Med. 2006; 23:857–66.
7. EURODIAB ACE Study Group. Variation and trends in incidence of childhood diab-etes in Europe. Lancet.2000;355:873–6.
8. Patterson CC, Dahlquist GG, Gyurus E, Green A and Soltesz G. Incidence trends for childhood type 1 diabetes in Europe during 1989–2003 and predicted new cases 2005–20: a multicentre prospective registr-ation study. Lancet. 2009;373:2027–33.
9. Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004; 82:844–51.
10. Kempen JH, O'Colmain BJ, Leske MC, Haffner SM, Klein R, Moss SE et al. The prevalence of diabetic retinopathy among adults in the United States. Archives of Ophthalmology. 2004;122:552–63.
11. Matthews DR, Stratton IM, Aldington SJ, Holman RR, Kohner EM. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69. Archives of Ophthalmology. 2004; 122(11):1631–40.
12. White NH, Cleary PA, Dahms W, Goldstein D, Malone J and Tamborlane WV. Beneficial effects of intensive therapy of diabetes during adolescence: Outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). The Journal of Pediatrics.2001; 139(6):804–12.
13. Cappellini MD and Fiorelli G. Glucose-6-phosphate dehydrogenase deficie-ncy. Lancet. 2008;371:64–74.
14. World Health Organization Working Group. Glucose-6-phosphate dehydrogenase deficiency. WHO Working Group. Bull World Health Organ. 1989;67:601–11.
15. Carette C, Dubois-Laforgue D, Gautier JF and Timsit J. Diabetes mellitus and glucose-6-phosphate dehydrogenase deficiency: from one crisis to another. Diabetes Metab. 2011;37:79–82.
16. Cocco P, Todde P, Fornera S, Manca MB, Manca M, Sias AR. Mortality in a cohort of men expressing the Glucose-6-Phosphate Dehydrogenase deficien-cy. Blood. 1998;91:706–9.
17. Pinna A, Carru C, Solinas G, Zinellu A and Carta F. Glucose-6-phosphate dehydrogenase deficiency in retinal vein occlusion. Invest Ophthalmol Vis Sci. 2007;48:2747–52.
18. Meloni L, Manca MR, Loddo I, Cioglia G, Cocco P, Schwartz Aet al. Glucose-6-phosphate dehydrogenase deficiency protects against coronary heart disease. J Inherit Metab Dis. 2008;31:412–7.
19. Cappai G, Songini M, Doria A, Cavallerano JD and Lorenzi M. Increased prevalence of proliferative retinopathy in patients with type 1 diabetes who are deficient in glucose-6-phosphate dehyd-rogenase. Diabetologia.2011;54:1539–42.
20. Pinna A, Contini EL,Carru C and Solinas G. Glucose-6-Phosphate Dehydrogenase Deficiency and Diabetes Mellitus with Severe Retinal Complications in a Sardinian Population, Italy.Int J Med Sci. 2013;10(13):1907–13.
21. Lozano R, Naghvi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lan-cet. 2012;380:2095–128.
22. Das P and Samarasekara U. The story of GBD 2010: A “super human” effort. Lancet. 2012;380:2067–70.
23. Vos T, Flaxman AD, Naghvi M, Lozano R, MicahudC, Ezzati M et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010. Lan-cet. 2012;380:2163–96.
24. Diabetes Epidemiology Research International Group Secular trends in incidence of childhood IDDM in 10 countries. Diabetes. 1990;39:858–64.
25. Lithovius R , Harjutsalo V, Forsblom C and Groop PH.Cumulative cost of prescription medication in outpatientswith type 1 diabetes in Finland. Diabetologia. 2011;54:496–503.
26. Asian-Pacific Type 2 Diabetes Policy Group. Type 2 Diabetes Practical Targetsand Treatments. Screening, Diagn-osis, Management, Treatment, Monitoring, Education, Prevention. Fourth edition. 2005.
27. World Health Organization Department of Non-communicable Disease Surveillance. Definition, Diagnosis, and Classification of Diabetes Mellitus and its Complic-ations. Geneva. 1999
28. Brewer GJ, Tarlov A,and Alving A. Methaemoglobin reduction test: a new, simple, in vitro test for identifying primaquine-sensitivity. Bull World Health Organ. 1960;22:633–40.
29. Beutler Eand Baluda MC. Methemoglobin Reduction: Studies of the interaction between cell populations and of the role of methylene blue. Blood. 1963;22:323–33.
30. Scottish Diabetic Retinopathy Screening Collaborative. National diabetes retino-pathy screening. Available fromwww.nd-rs.scot.nhs.uk.
31. Cappadoro M, Giribaldi G, O'Brien E, Turrini F, Mannu F, Ulliers D et al. Early phagocytosis of glucose-6-phosphate dehydrogenase (G6PD)-deficient erythroc-ytes parasitized by Plasmodium falciparum may explain malaria protection in G6PD deficiency. Blood. 1998;92:2527–34.
32. Nikolaidis MG, Jamurtas AZ, Paschalis V, Kostaropoulos IA, Kladi-Skandali A, Vera Balamitsi V et al. Exercise-induced oxid-ative stress in G6PD-deficient individu-als. Med Sci Sports Exerc 2006;28:1443–50.